Zhang Q, Mi M, E T, Fu X, Bao N, Pan L
Front Vet Sci. 2024; 11:1423604.
PMID: 39564187
PMC: 11575259.
DOI: 10.3389/fvets.2024.1423604.
Choi S, Lee J, Ko S, Hong S, Jin H
Biomol Ther (Seoul). 2024; 32(6):708-722.
PMID: 39448393
PMC: 11535297.
DOI: 10.4062/biomolther.2024.146.
Qi Y, Deng S, Wang K
Am J Cancer Res. 2024; 14(9):4172-4196.
PMID: 39417188
PMC: 11477839.
DOI: 10.62347/KIVS3169.
Si Q, Bai M, Wang X, Wang T, Qin Y
Front Immunol. 2024; 15:1420463.
PMID: 39308869
PMC: 11412844.
DOI: 10.3389/fimmu.2024.1420463.
Linazi G, Maimaiti A, Abulaiti Z, Shi H, Zhou Z, Aisa M
Heliyon. 2024; 10(17):e36989.
PMID: 39286119
PMC: 11402926.
DOI: 10.1016/j.heliyon.2024.e36989.
Targeting EGFR with molecular degraders as a promising strategy to overcome resistance to EGFR inhibitors.
Wang Q, Zhu Y, Pei J
Future Med Chem. 2024; 16(18):1923-1944.
PMID: 39206853
PMC: 11485768.
DOI: 10.1080/17568919.2024.2389764.
Targeting cytokine and chemokine signaling pathways for cancer therapy.
Yi M, Li T, Niu M, Zhang H, Wu Y, Wu K
Signal Transduct Target Ther. 2024; 9(1):176.
PMID: 39034318
PMC: 11275440.
DOI: 10.1038/s41392-024-01868-3.
SNX16 is required for hepatocellular carcinoma survival via modulating the EGFR-AKT signaling pathway.
Yuan L, Meng Y, Xiang J
Sci Rep. 2024; 14(1):13093.
PMID: 38849490
PMC: 11161632.
DOI: 10.1038/s41598-024-64015-6.
Hepatocellular Carcinoma: Old and Emerging Therapeutic Targets.
Pessino G, Scotti C, Maggi M, Immuno-Hub Consortium
Cancers (Basel). 2024; 16(5).
PMID: 38473265
PMC: 10931414.
DOI: 10.3390/cancers16050901.
Epigallocatechin-3-Gallate and Genistein for Decreasing Gut Dysbiosis, Inhibiting Inflammasomes, and Aiding Autophagy in Alzheimer's Disease.
Muraleedharan A, Ray S
Brain Sci. 2024; 14(1).
PMID: 38275516
PMC: 10813550.
DOI: 10.3390/brainsci14010096.
D-mannose induces TFE3-dependent lysosomal degradation of EGFR and inhibits the progression of NSCLC.
Sun X, Dai Y, He J, Li H, Yang X, Dong W
Oncogene. 2023; 42(47):3503-3513.
PMID: 37845392
DOI: 10.1038/s41388-023-02856-7.
Emerging roles of PHLPP phosphatases in lung cancer.
Xia X, Pi W, Chen M, Wang W, Cai D, Wang X
Front Oncol. 2023; 13:1216131.
PMID: 37576883
PMC: 10414793.
DOI: 10.3389/fonc.2023.1216131.
MFN2 suppresses clear cell renal cell carcinoma progression by modulating mitochondria-dependent dephosphorylation of EGFR.
Luo L, Wei D, Pan Y, Wang Q, Feng J, Yu B
Cancer Commun (Lond). 2023; 43(7):808-833.
PMID: 37378422
PMC: 10354417.
DOI: 10.1002/cac2.12428.
Cetuximab enhances radiosensitivity of esophageal squamous cell carcinoma cells by G2/M cycle arrest and DNA repair delay through inhibiting p-EGFR and p-ERK.
Zhao G, Feng L, Ye T, Liu Y, Fan L, Ye C
Thorac Cancer. 2023; 14(22):2127-2138.
PMID: 37337933
PMC: 10396788.
DOI: 10.1111/1759-7714.14995.
Confinement of unliganded EGFR by tetraspanin nanodomains gates EGFR ligand binding and signaling.
Sugiyama M, Brown A, Vega-Lugo J, Borges J, Scott A, Jaqaman K
Nat Commun. 2023; 14(1):2681.
PMID: 37160944
PMC: 10170156.
DOI: 10.1038/s41467-023-38390-z.
A new paradigm for epidermal growth factor receptor expression exists in PTC and NIFTP regulated by microRNAs.
Al-Abdallah A, Jahanbani I, Ali R, Al-Brahim N, Prasanth J, Al-Shammary B
Front Oncol. 2023; 13:1080008.
PMID: 37114127
PMC: 10126268.
DOI: 10.3389/fonc.2023.1080008.
Zonulin as a Potential Therapeutic Target in Microbiota-Gut-Brain Axis Disorders: Encouraging Results and Emerging Questions.
Veres-Szekely A, Szasz C, Pap D, Szebeni B, Bokrossy P, Vannay A
Int J Mol Sci. 2023; 24(8).
PMID: 37108711
PMC: 10139156.
DOI: 10.3390/ijms24087548.
Cardiac Overexpression of Chil1 Improves Wound Healing to Prevent Cardiac Rupture After Myocardial Infarction.
Ye T, Yang B, Wei P, Niu K, Li T, Wang D
J Cardiovasc Transl Res. 2022; 16(3):608-623.
PMID: 36348231
DOI: 10.1007/s12265-022-10328-8.
Congenital medulloblastoma in two brothers with SUFU-mutated Gorlin-Goltz syndrome: Case reports and literature review.
Chen Y, Zhang H, Zhao Y, Ma J
Front Oncol. 2022; 12:988798.
PMID: 36313636
PMC: 9603755.
DOI: 10.3389/fonc.2022.988798.
Inhibition of EGFR Overcomes Acquired Lenvatinib Resistance Driven by STAT3-ABCB1 Signaling in Hepatocellular Carcinoma.
Hu B, Zou T, Qin W, Shen X, Su Y, Li J
Cancer Res. 2022; 82(20):3845-3857.
PMID: 36066408
PMC: 9574378.
DOI: 10.1158/0008-5472.CAN-21-4140.
